Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Cediranib Maleate and gefitinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not
yet known whether cediranib maleate given together with gefitinib is more effective than
cediranib maleate given alone in treating patients with recurrent or progressive
glioblastoma.
PURPOSE: This randomized phase II trial is studying the side effects of giving cediranib
maleate together with gefitinib and to see how well it works compared with giving cediranib
maleate together with a placebo in treating patients with recurrent or progressive
glioblastoma.